Research

Hormonal

Unimolecular tetra-receptor agonists (TC4) simultaneously activate GLP-1R, GIPR, GcgR, and Y2R, resulting in superior metabolic efficacy (weight loss and glycemic control) compared to mono- or dual-agonists by leveraging synergistic receptor engagement.

This research describes a new class of peptide drugs that target four metabolic receptors (GLP-1, GIP, Glucagon, and PYY) simultaneously. In preclinical studies, this approach showed strong potential for treating obesity and type 2 diabetes with fewer side effects like nausea than older drugs. It is not yet available for human use.

LimitedSupportsMEDIUM confidence
These TC constructs were rationally designed toward retaining high potency and efficacy across all four target receptors... The ability to achieve broad-spectrum receptor activation within a single peptide framework represents a promising advancement in the field of metabolic therapeutics, with implications for the treatment of obesity, T2D, and associated comorbidities.
Tristan C. Dinsmore et al. · Journal of the American Chemical Society · 2025

Why this rating

Preclinical in vitro and in vivo data; no human clinical trial results are presented in this manuscript.

Source

Molecular Design of Unimolecular Tetra-Receptor Agonists

Tristan C. Dinsmore et al. · Journal of the American Chemical Society · 2025

DOI 10.1021/jacs.5c04095

mechanism_onlyCited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →